Delisting risk
MIRA Pharmaceuticals (MIRA)
Develops oral small-molecule candidates for pain, obesity, and addiction-related disorders.
$0.8600
Pre-market−0.01 (−0.58%)
At close$0.8650(+0.58%)
In millions of USD, except per-share figures
| In millions | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3 | 3 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 6 | 1 | 1 | |
| Research & development | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 1 |
| 2 | 3 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 5 | 1 | 0 | |
| General & administrative | 2 | 3 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 5 | 1 | 0 |
| Operating income | −3 | −3 | −2 | −2 | −2 | −2 | −2 | −2 | −1 | −6 | −1 | −1 |
| 0 | −3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Interest income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest expense | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income | 0 | — | 0 | 0 | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income before tax | −4 | −6 | −2 | −2 | −2 | −2 | −2 | −2 | −1 | −6 | −1 | −1 |
| Net income from continuing operations | −4 | −6 | −2 | −2 | −2 | −2 | −2 | −2 | −1 | −6 | −1 | −1 |
| Net income | −4 | −6 | −2 | −2 | −2 | −2 | −2 | −2 | −1 | −6 | −1 | −1 |
| EPS, basic | −$0.24 | −$0.39 | −$0.09 | −$0.11 | −$0.14 | −$0.16 | −$0.11 | −$0.09 | −$1.18 | −$0.14 | −$0.03 | −$0.03 |
| EPS, diluted | −$0.24 | −$0.39 | −$0.09 | −$0.11 | −$0.14 | −$0.16 | −$0.11 | −$0.09 | −$1.18 | −$0.14 | −$0.03 | −$0.03 |
| Weighted average shares, basic | 15 | 15 | 20 | 15 | 15 | 15 | 17 | 17 | 19 | 24 | 42 | 42 |
| Weighted average shares, diluted | 15 | 15 | 20 | 15 | 15 | 15 | 17 | 17 | 19 | 24 | 42 | 42 |
| EBITDA | 0 | 0 | −2 | −2 | 0 | −2 | −2 | −2 | −1 | −6 | −1 | −1 |
| Depreciation & amortization | 3 | 3 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBIT | −3 | −3 | −2 | −2 | −2 | −2 | −2 | −2 | −1 | −6 | −1 | −1 |